iiinova — where your digital self keeps evolving

Avantika Gupta @avantikagupta.bsky.social · 10/11/2025

More mechanisms of resistance to anti-HER2 ADCs, this time with a focus on loss of target interaction!

Reposted by Avantika Gupta

Elizabeth McKenna @elizsmckenna.bsky.social · 10/11/2025

Now online in Cancer Discovery @aacrjournals.bsky.social: Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding - by Wanyi Chen, @joshdragomd.bsky.social, @saratchandarlapaty.bsky.social, and colleagues doi.org/10.1158/2159... @mskcancercenter.bsky.social

065

Avantika Gupta @avantikagupta.bsky.social · 17/06/2025

Amazing to have our work featured on the cover of the latest issue of @natgenet.nature.com! The artwork, like the science, is a collaborative creation with everyone’s fingerprints 🎉 www.nature.com/articles/s41...

141

Reposted by Avantika Gupta

Sarat Chandarlapaty @saratchandarlapaty.bsky.social · 04/06/2025

Published online today - work led by Yanyan Cai: Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers | Science Translational Medicine www.science.org/doi/10.1126/...

science.org

Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers

NR2F2 modulates the ER cistrome, coregulator interactions, and chromatin accessibility to promote endocrine resistance in ER+ breast cancer.

083

Reposted by Avantika Gupta

Sarat Chandarlapaty @saratchandarlapaty.bsky.social · 16/05/2025

Published online today - work from our team led by Avantika Gupta, revealing how APOBEC3 mutagenesis promotes resistance to several targeted therapies in breast cancer. Check it out! urldefense.com/v3/__https:/...

urldefense.com

APOBEC3 mutagenesis drives therapy resistance in breast cancer

Nature Genetics - Analysis of a large cohort of metastatic breast cancer samples shows that APOBEC mutational signatures are enriched in post-treatment samples. APOBEC activity was also associated...

063

Avantika Gupta @avantikagupta.bsky.social · 28/04/2025

@saratchandarlapaty.bsky.social expertly summarizing our work on how underlying genomic instability in breast cancer leads to therapy resistance leaving with key ideas on how we might target them! Come see me expand on the role of APOBEC3 mutagenesis in these processes tomorrow morning at #AACR25!

021

Avantika Gupta @avantikagupta.bsky.social · 14/12/2024

Congratulations to @reikudo.bsky.social for the beautiful work inspiring current+future studies! #SABCS24

031

Avantika Gupta @avantikagupta.bsky.social · 13/12/2024

So honored to have gotten the opportunity to present our work showing a prevalent role of APOBEC3 mutagenesis in driving therapy resistance in breast cancer at #SABCS24!

172

Reposted by Avantika Gupta

Matt Sikora @mjsikora.bsky.social · 12/12/2024

Great work from Dr Avantika Gupta in @saratchandarlapaty.bsky.social lab, linking APOBEC mutagenesis to facilitating therapy resistance in HR+ breast cancer. Lots of intriguing vulnerabilities to target that would be relevant in a lot of breast cancers! #SABCS24 www.biorxiv.org/content/10.1...

biorxiv.org

APOBEC3 mutagenesis drives therapy resistance in breast cancer

Acquired genetic alterations commonly drive resistance to endocrine and targeted therapies in metastatic breast cancer[1][1]–[7][2], however the underlying processes engendering these diverse alterati...

092

Reposted by Avantika Gupta

Sarat Chandarlapaty @saratchandarlapaty.bsky.social · 12/12/2024

Fantastic presentation #SABCS by @avantikagupta.bsky.social on apobec3 in breast cancer. Demonstrating the role of this process in promoting therapy resistance.

1144

Avantika Gupta @avantikagupta.bsky.social · 12/12/2024

Congratulations to @caiy0219.bsky.social for an excellent poster presentation today! 👏🏽 Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!

052